LYCOS RETRIEVER 
Bronchitis: Treatments
built 657 days ago
The two main types of bronchitis are very different in their onset and treatment: acute bronchitis and chronic bronchitis. Acute bronchitis is often related to an upper respiratory infection arising from a common cold or flu. Chronic bronchitis arises from various long-term problems, notably from smoking.
Source:
[A]t the first signs of a lung infection, people with chronic bronchitis should seek immediate medical treatment. Waiting until an infection is well established, usually leads to hospitalization and long intensive care (ICU) stays.
Source:
Suggestion about homeopathic treatment: Homoeopathic medicines are very effective in managing acute expressions of bronchitis as well as play a vital role in preventing relapse of the condition in chronic bronchitis. Chronic and allergic bronchitis are actually constitutional disorders that show local expression at the level of lungs. Hence these call for an in-depth constitutional approach towards its management.
Source:
There is no cure for chronic bronchitis. The goal of treatment is to relieve symptoms and prevent complications. It is crucial to quit smoking to prevent chronic bronchitis from getting worse. Any other respiratory irritants should be avoided.
Source:
In subjects with chronic bronchitis or COPD, treatment with mucolytics was associated with a small reduction in acute exacerbations and a reduction in the total number of days of disability. This benefit may be greater in individuals who have frequent or prolonged exacerbations.
Source:
Risk stratification is the recommended approach for treatment of acute exacerbation of chronic bronchitis (AECB) to optimize the chances of clinical success. The suggested oral therapy for "simple or uncomplicated" AECB, which is predominantly a result of infection due to Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae, includes advanced macrolides and 2nd- or 3rd-generation cephalosporins, in addition to the older 1st-line agents (aminopenicillins, doxycycline, trimethoprim/sulfamethoxazole, and erythromycin). In light of increasing resistance of H. influenzae and S. pneumoniae to the older agents, the specific directed structural modification of the cephalosporin nucleus resulted in the development of extended-spectrum 3rd-generation oral cephems with enhanced beta-lactamase stability and improved activity against Gram-positive pathogens (penicillin-susceptible S. pneumoniae and oxacillin-susceptible Staphylococcus aureus). Analysis of results of double-blind randomized clinical trials assessing efficacy of the extended-spectrum oral cephems published since 2000 demonstrates that both cefdinir and cefditoren have similar point estimates of success in comparison to their comparators (cefuroxime, cefprozil, or Locarbacef), when either the clinical cure or the bacteriologic response was analyzed. Thus, oral extended-spectrum 3rd-generation cephems, which retain antimicrobial efficacy against the traditional respiratory pathogens despite changing resistance patterns, offer excellent coverage against the key pathogens involved in simple or uncomplicated AECB.
Source:
MORE ABOUT
Treatments